Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 184 clinical trials
Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema

This study will evaluate the effects of add-on carotenoid plus anti-oxidant nutritional supplementation to standard anti-vascular endothelial growth factor therapy for subjects with center

  • 0 views
  • 24 Jan, 2021
  • 1 location
  • 0 views
  • 23 Jan, 2021
  • 1 location
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

Apatinib, an oral inhibitor of vascular endothelial growth factor receptor 2VEGFR-2, Induces Transporter Pgp function in vitro. This study in patients with advanced cancer

growth factor
cancer
solid tumour
advanced cancer
  • 0 views
  • 24 Jan, 2021
  • 1 location
Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis (revascularization).

revascularisation
percutaneous coronary intervention
bypass graft
coronary artery bypass graft
arteriopathy
  • 42 views
  • 24 Feb, 2021
  • 11 locations
A Phase 1 Study of CX1003 (Kanitinib) in Patients With Advanced Solid Tumors

CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR

kinase inhibitor
growth factor
measurable disease
VEGFR2
solid tumour
  • 0 views
  • 27 Jan, 2021
  • 1 location
Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma

Currently, there is no standard treatment for primary pulmonary lymphoepithelioid carcinoma. Apatinib is a new kind of Vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase

ct scan
measurable disease
lung cancer
lung carcinoma
cancer
  • 0 views
  • 22 Jan, 2021
  • 1 location
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy

is to evaluate the survival in these patients treated with apatinib (YN968D1), an inhibitor of vascular endothelial growth factor receptor (phase IIa) and to compare the survival in these patients

carcinoma
absolute neutrophil count
liver ultrasound
apatinib
nasopharyngeal carcinoma
  • 9 views
  • 21 Jan, 2021
  • 2 locations
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of vascular endothelial growth factor receptor 2VEGFRFGFRfibroblast growth factor receptor

neutrophil count
blood transfusion
EGFR
lung cancer
ct scan
  • 0 views
  • 24 Jan, 2021
  • 6 locations
First-line Chemotherapy for Recurrent Cervical Cancer

The response rate of traditional first-line chemotherapy for recurrent or persistent advanced cervical cancer was low. This single arm, open, phase II trial would recruit 37 eligible patients. A combination of cisplatin, paclitaxel and apatinib would be given for first 23 patients. If at least 13 patients achieved complete or …

creatinine clearance rate
carcinoma
chemotherapy regimen
adenocarcinoma
treatment regimen
  • 2 views
  • 23 Jan, 2021
Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

growth factor (PDGF) by vascular endothelial growth factor (VEGF) potentiates a pathologic, sustained activation of PDGF receptors that is critical to the progression of experimental PVR. VEGF blockade

  • 0 views
  • 26 Jan, 2021
  • 1 location